AroCell is participating in the Stockholm Corporate Finance 15th Life Science Capital Markets Days on March 8 - 9, 2023 at the IVA conference center in Stockholm. AroCell's CEO Anders Hultman presents on March 9th at 8:00 – 8:30 the latest developments and the future of the company.

Stockholm Corporate Finance organizes the capital market days for the fifteenth year in a row in collaboration with Financial Hearings and Infront Direkt Studios, which is an independent part of Nyhetsbyrån Direkt. If you want to register as a participant for the capital markets day, use this link, Stockholm Corporate Finance 15e Life Science Seminarium on March 8-9, 2023 (lyyti.fi)

Contacts

Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@arocell.com

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.arocell.com

Attachments

AroCell presents at Stockholm Corporate Finance 15th Life Science Capital Market Days